Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. Sold as Opdivo. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Nivolumab (sold as Opdivo), first approved Dec 22, 2014, with 65 new uses approved and 0 published complete response letters.
First approved: Dec 22, 2014
Applications: 2
New uses approved: 65
Complete response letters: 0
Medicare spending, 2025: $2.06B
Orphan exclusivity until: Mar 20, 2033
First approved in the EU: Jun 19, 2015
First approved in Japan: Jul 4, 2014
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 6 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
OpdivoDrugs with a new indication and new dosage for the treatment of unresectable, advanced or recurrent microsatellite instability-high (MSI-High) colorectal… · Ono Pharmaceutical Co., Ltd. · Aug 25, 2025
OpdivoDrugs with a new indication and a new dosage for the treatment of unresectable hepatocellular carcinoma. · Ono Pharmaceutical Co., Ltd. · Jun 24, 2025
OpdivoDrugs with a new indication and a new dosage for the treatment of unresectable urothelial carcinoma. · Ono Pharmaceutical Co., Ltd. · Dec 27, 2024
OpdivoDrugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent epithelial skin malignancies. · Ono Pharmaceutical Co., Ltd. · Feb 9, 2024
OpdivoDrugs with a new indication and a new dosage for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). · Ono Pharmaceutical Co., Ltd. · Nov 24, 2023
OpdivoDrugs with a new indication and a new dosage for the preoperative adjuvant treatment for non-small-cell lung cancer. · Ono Pharmaceutical Co., Ltd. · Mar 27, 2023
OpdivoDrugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent esophageal cancer. · Ono Pharmaceutical Co., Ltd. · May 26, 2022
OpdivoDrugs with a new indication and a new dosage for the postoperative adjuvant therapy for urothelial carcinoma. · Ono Pharmaceutical Co., Ltd. · Mar 28, 2022
Clinical Trials
721 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA